Metformin, a well‐known AMPK agonist, has been widely used as the first‐line drug for
treating type 2 diabetes. There had been a significant concern regarding the use of …

Diabetics have higher morbidity and mortality in cardiovascular disease (CVD). A variety of
antidiabetic agents are available for clinical choice. Cardiovascular (CV) safety assessment …

Metformin is a plant-based drug belonging to the class of biguanides and is known to treat
type-2 diabetes mellitus (T2DM). The drug, combined with controlling blood glucose levels …

Metformin is currently the first-line drug treatment for type 2 diabetes. Besides its glucose-
lowering effect, there is interest in actions of the drug of potential relevance to cardiovascular …

Cardiovascular mortality is a major cause of death among in type 2 diabetes (T2DM).
Endothelial dysfunction (ED) is a well-known important risk factor for the development of …

Diabet. Med. 27, 1097–1106 (2010) Abstract Clinical studies in Type 2 diabetes mellitus
have shown that the effects of metformin go beyond improving HbA1c and include …

OBJECTIVE—Clinical studies have reported that metformin reduces cardiovascular end
points of type 2 diabetic subjects by actions that cannot solely be attributed to glucose …

Backgrounds: Our previous work revealed that AMP-activated protein kinase (AMPK)
activation inhibits vascular smooth muscle cell migration in vitro by phosphorylating PDZ …

Metformin is a biguanide family member used in the treatment of type 2 diabetes and one of
the most widely prescribed antidiabetes drugs. This drug increases the peripheral uptake of …

Atherosclerosis is a common cause of cardiovascular disease, which, in turn, is often fatal.
Today, we know a lot about the pathogenesis of atherosclerosis. However, the main …